Genes, Patents, and Big Business: at 23andMe, are you the Customer or the Product?
By Adrianne Jeffries,
The Verge
| 12. 12. 2012
Ethical questions swirl as the personal genetics company starts scaling up
It’s been six years since DNA testing service
23andMe launched. In that time, about 180,000 people around the world have sent their saliva to the Mountain View-based company to test for more than 200 genetic traits and markers.
That’s not an inconsequential number, but it shows that personal DNA testing just isn’t a very large market yet. As a result, 23andMe has decisively shifted its focus to building and monetizing a giant database of genetic information, rather than satisfying personal curiosity. We’re entering the era of personal genetics as big business.
The company announced yesterday that it has raised
$50 million from name-brand investors including Google Ventures and Russian billionaire Yuri Milner to do just that. 23andMe is run by Anne Wojcicki, who is a 10-year veteran of healthcare investing and the wife of Google cofounder Sergey Brin; she and her husband both plunked down cash as well.
It’s been a big year for the personal genetics industry. Last week, personal genetics testing provider deCODE Genetics was bought by biotech company Amgen for $415 million. Genetics diagnostics startup Navigenics was...
Related Articles
By Annika Inampudi, Science | 07.10.2025
Before a baby in the United States reaches a few days old, doctors will run biochemical tests on a few drops of their blood to catch certain genetic diseases that need immediate care to prevent brain damage or other serious...
By Geoffrey A. Fowler, The Washington Post | 07.17.2025
Nearly 2 million people protected their privacy by deleting their DNA from 23andMe after it declared bankruptcy in March. Now it’s back with the same person in charge — and I still don’t trust it.
Nor do the attorneys general...
By Elizabeth Dwoskin and Yeganeh Torbati, The Washington Post | 07.16.2025
A group of well-heeled, 30-something women sat down to dinner last spring at a table set with pregnancy-friendly mocktails and orchids, ready to hear a talk about how to optimize their offspring.
Noor Siddiqui, the founder of an embryo-screening start-up...
By Suzanne O'Sullivan, New Scientist | 07.09.2025
Rare diseases are often hard to spot. They can evade detection until irreversible organ damage or disability has already set in. Last month, in the hope of preventing just this type of harm, the UK’s health secretary, Wes Streeting, announced...